Market News
Stay updated with the latest market trends, earnings, and economic indicators.
TVS Motor onboards Ravindran Shanmugam as independent director
TVS Motor Company has appointed Ravindran Shanmugam as an independent director. Shanmugam brings extensive experience in technology and consumer-focused businesses. His expertise in digital transformation and AI-led platforms will support TVS Motor's future growth ambitions. The appointment is effective May 13 and requires shareholder approval. Shanmugam's insights will contribute to the company's strategic direction.
India's EV battery demand to grow 10 times to 200 GWh by 2032: IESA
India's electric vehicle battery demand will surge tenfold by 2032. This growth presents significant opportunities in component localization and supply chain development. The market is transforming with advancements in batteries, motors, and manufacturing. Electric two-wheelers lead sales, but passenger cars and light commercial fleets will drive future expansion. New battery chemistries and motor technologies are emerging.
ET Alpha Wealth Summit: Market titans decode AI, wealth creation & India’s next investment cycle
As markets grow volatile, the Economic Times' Alpha Wealth Summit in Mumbai will gather experts to discuss future wealth creation. Sessions will cover finding alpha, building a Rs 100 crore portfolio in a lower-return environment, and navigating India's next decade amidst AI's rise.
Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked target
Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despite a weak Q4 performance. The stock hit an intraday high of Rs 1,432.10 as investors focused on future growth prospects over near-term earnings pressure.
Tata Motors shares decline over 3% after Q4 results. What are Motilal Oswal and Nuvama saying?
Tata Motors (Commercial Vehicles) reported strong quarterly earnings with a sharp rise in net profit and revenue, but its stock fell by over 3% amid cautious sentiment on the commercial vehicle sector outlook. Brokerages remain split, with neutral to bullish views on future growth driven by exports and industry recovery.
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vial
Eli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in India. Eli Lilly has launched Lormalzi, a new monthly treatment for early Alzheimer's disease. This drug targets amyloid plaques. It will be available in India this month. The treatment costs 91,688 rupees per vial.
From oncology to obesity, Pfizer bets big on India for its next growth wave
Pfizer is focusing on India for future growth. The company plans to launch new medicines quickly and at affordable prices. India is seen as a crucial market for new treatments in cancer, obesity, and vaccines. Pfizer is also working on local clinical studies for future drug launches.
Mumbai’s eastern corridor gains traction as firms expand beyond BKC
Mumbai's commercial landscape is shifting from traditional hubs like BKC and Nariman Point to emerging micro-markets such as Chembur, driven by escalating costs. The Epicentre, a Grade-A development in Chembur, offers businesses a strategic, cost-effective alternative with enhanced connectivity and future-ready workspaces, positioning it for Mumbai's next growth phase.
Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividend
Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also declined. Despite these figures, key therapies and trade generics business showed strong growth. The company plans to focus on expanding its markets and developing its future pipeline. A final dividend of Rs 13 per equity share has been recommended.
US CPI records biggest jump in 3 years: Can the Fed raise interest rates after hot inflation data?
The US consumer price index has jumped to a three-year high of 3.8%, prompting questions about potential interest rate hikes by the Federal Reserve. Economists weigh in on the impacts of rising oil prices and economic stability, leaving the market in suspense about future monetary policy.
US Stock Market: Why investors are betting big on Kopin’s AI future - The Economic Times
US Stock Market: Why investors are betting big on Kopin’s AI futureThe Economic Times